Prostate Cancer Treatments

Find Prostate Cancer Treatments

Generic Name

Abiraterone Acetate

Brand Names

Abiraterone, Abirtega, Akeega, YONSA, Zytiga

FDA approval date: April 28, 2011

Classification: Cytochrome P450 17A1 Inhibitor

Form: Tablet

What is Abiraterone (Abiraterone Acetate)?

Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer , Metastatic high-risk castration-sensitive prostate cancer Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with, metastatic castration-resistant prostate cancer . , metastatic high-risk castration-sensitive prostate cancer .

Approved To Treat

Prostate Cancer

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Phase II Clinical Trial Evaluating the Safety and Efficacy of Low Dose Naltrexone (LDN) for the Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in this study are being treated with hormone therapy (also called androgen deprivation therapy, or ADT). Some may also be taking newer hormone medicines such as apalutamide, daralutamide, enzalutamide, or abiraterone.

Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The goal of this phase 3 clinical trial is to determine the clinical effectiveness and cost effectiveness of using lower doses of Androgen Receptor Pathway Inhibitors (ARPI) to treat patients with prostate cancer that has spread (metastasized). The main questions it aims to answer are: 1. if overall survival for reduced dose ARPI is not worse than standard dose ARPI when treating patients with met...

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

Enrollment Status: Recruiting

Publish Date: September 03, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

View All Clinical Trials